Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)

20.90 -0.31 (-1.46%) As of 12:04PM CST. Market open.

Shenzhen Kangtai Biological Products Co., Ltd.

No.18, Shutianpu Road
Guangming District
Shenzhen 518107
China
86 755 2698 8658
https://www.biokangtai.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,902

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Xiang Miao	President & Non-Independent Director	N/A	N/A	1973
Mr. Haifa Zheng	Vice Chairman & VP	N/A	N/A	1964
Ms. Hui Zhou	Chief Financial Officer	N/A	N/A	1972
Mr. Jiankai Liu	VP & Non-Independent Director	N/A	N/A	1970
Ms. Jin Tao	Board Secretary	N/A	N/A	1983

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company's products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, live attenuated varicella vaccine, and HIB conjugate vaccine. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is based in Shenzhen, China.

Corporate governance

Shenzhen Kangtai Biological Products Co., Ltd.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 5; Board: 10; Shareholder rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.